Company intelligence / Profile preview

Zipcode Bio

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Zipcode Bio is developing mRNA-based broad-protecting influenza vaccines using proprietary SHARP nanoparticle technology for targeted spleen and lung delivery. Early results have led to a $2M BARDA Patch Forward Prize for their partnership with Micron Biomedical to co-develop needle-free flu vaccines. Their platform offers advantages over traditional lipid nanoparticles, such as easier production, improved safety, and efficacy

Therapeutic areas: Infectious DiseasesPulmonology
Modalities: mRNA-based drugsNucleic acid
Industry: Biotech

Partnerships

Micron BiomedicalBiomedical Advanced Research and Development Authority (BARDA)

Beyond the preview

Go deeper on Zipcode Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zipcode Bio.

Explore the full profile